Karolinska Development AB Announces New Share Issue


STOCKHOLM - September 30, 2009. Karolinska Development AB (publ) has announced that the Board of Directors intends (conditional on approval by an Extraordinary General Meeting to be held on Wednesday 4th November 2009) to resolve on a new share issue. The new round of financing is planned for the end of 2009. SEB Enskilda will be appointed to act as leading bank with EFG Bank AB (publ) as co‐lead.

For more information please contact:

Conny Bogentoft, CEO
Karolinska Development AB
Cell phone +46 70 668 61 43

About Us

Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations.


Documents & Links